Tocilizumab: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| Line 2: | Line 2: | ||
*IL-6 antagonist |
*IL-6 antagonist |
||
*Indicated for [[COVID-19]] |
|||
==Dosing== |
==Dosing== |
||
| Line 12: | Line 13: | ||
==Safety== |
==Safety== |
||
=== Contraindications === |
|||
* Contraindications and relative contraindications include hypersensitivity, co-existing infection, immunosuppression, increase liver enzymes. |
|||
===Infections=== |
===Infections=== |
||
Latest revision as of 23:00, 13 January 2022
Background
- IL-6 antagonist
- Indicated for COVID-19
Dosing
- SARS-CoV-2 with acutely declining patients, as a single dose infused over 60 minutes
- Weight ≤40 kg: 8 mg/kg
- Weight >40 and ≤65 kg: 400 mg
- Weight >65 and ≤90 kg: 600 mg
- Weight >90 kg: 800 mg
Safety
Contraindications
- Contraindications and relative contraindications include hypersensitivity, co-existing infection, immunosuppression, increase liver enzymes.
Infections
- In one cohort study, serious bacterial infections occured in about 7%, with no viral or fungal infections seen1
- Compared to TNF-α inhibitors, has a higher risk of serious bacterial infection, skin and soft tissue infection, and diverticulitis2
References
- ^ Ajinkya Pawar, Rishi J Desai, Daniel H Solomon, Adrian J Santiago Ortiz, Sara Gale, Min Bao, Khaled Sarsour, Sebastian Schneeweiss, Seoyoung C Kim. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Annals of the Rheumatic Diseases. 2019;78(4):456-464. doi:10.1136/annrheumdis-2018-214367.
- ^ Veronika R. Lang, Matthias Englbrecht, Jürgen Rech, Hubert Nüsslein, Karin Manger, Florian Schuch, Hans-Peter Tony, Martin Fleck, Bernhard Manger, Georg Schett, Jochen Zwerina. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology. 2011;51(5):852-857. doi:10.1093/rheumatology/ker223.
